Sanofi Income from Continuous Operations 2010-2024 | SNY
Sanofi annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Sanofi income from continuous operations for the quarter ending September 30, 2024 was $3.127B, a 13.21% increase year-over-year.
- Sanofi income from continuous operations for the twelve months ending September 30, 2024 was $4.961B, a 49.27% decline year-over-year.
- Sanofi annual income from continuous operations for 2023 was $5.883B, a 34.18% decline from 2022.
- Sanofi annual income from continuous operations for 2022 was $8.939B, a 20.33% increase from 2021.
- Sanofi annual income from continuous operations for 2021 was $7.429B, a 47.34% decline from 2020.
Sanofi Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$5,883 |
| 2022 |
$8,939 |
| 2021 |
$7,429 |
| 2020 |
$14,107 |
| 2019 |
$3,291 |
| 2018 |
$5,224 |
| 2017 |
$4,422 |
| 2016 |
$4,964 |
| 2015 |
$5,010 |
| 2014 |
$5,994 |
| 2013 |
$5,147 |
| 2012 |
$6,605 |
| 2011 |
$11,533 |
| 2010 |
$12,554 |
| 2009 |
$11,620 |
Sanofi Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-09-30 |
$3,127 |
| 2024-06-30 |
$1,203 |
| 2024-03-31 |
$1,244 |
| 2023-12-31 |
$-613 |
| 2023-09-30 |
$2,762 |
| 2023-06-30 |
$1,578 |
| 2023-03-31 |
$2,156 |
| 2022-12-31 |
$3,283 |
| 2022-09-30 |
$2,094 |
| 2022-06-30 |
$1,298 |
| 2022-03-31 |
$2,263 |
| 2021-09-30 |
$2,763 |
| 2021-06-30 |
|
| 2021-03-31 |
$1,902 |
| 2020-09-30 |
$2,290 |
| 2020-03-31 |
$1,870 |
| 2019-09-30 |
$2,085 |
| 2019-03-31 |
$1,303 |
| 2018-03-31 |
$1,286 |
| 2017-12-31 |
$48 |
| 2017-09-30 |
$1,799 |
| 2017-06-30 |
$1,181 |
| 2017-03-31 |
$1,394 |
| 2016-12-31 |
$842 |
| 2016-09-30 |
$1,889 |
| 2016-06-30 |
$1,115 |
| 2016-03-31 |
$1,118 |
| 2015-09-30 |
$1,837 |
| 2015-06-30 |
$1,470 |
| 2014-06-30 |
$1,103 |
| 2013-06-30 |
$637 |
| 2012-06-30 |
$1,569 |
| 2012-03-31 |
$2,414 |
| 2011-12-31 |
$1,887 |
| 2011-09-30 |
$2,803 |
| 2011-06-30 |
$1,453 |
| 2011-03-31 |
$3,187 |
| 2010-12-31 |
$595 |
| 2010-09-30 |
$2,219 |
| 2010-06-30 |
$2,219 |
| 2010-03-31 |
$3,204 |
| 2009-12-31 |
$1,658 |
| 2009-09-30 |
$3,290 |
| 2009-06-30 |
$3,227 |
| 2009-03-31 |
$2,817 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$128.465B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
